Comparison of Infliximab and Infliximab/Azathioprine for Maintenance Therapy in Korean Patients with Luminal Crohn's Disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Won, Hyun Sun | - |
dc.contributor.author | Park, Dong Il | - |
dc.contributor.author | Chon, Chang Uk | - |
dc.contributor.author | Seok, Hyo Sun | - |
dc.contributor.author | Kim, Tae Wan | - |
dc.contributor.author | Heo, Woon Je | - |
dc.contributor.author | Lee, Chang Kyun | - |
dc.contributor.author | Eun, Chang Soo | - |
dc.contributor.author | Han, Dong Soo | - |
dc.contributor.author | Lee, Suck-Ho | - |
dc.date.accessioned | 2021-08-12T04:46:13Z | - |
dc.date.available | 2021-08-12T04:46:13Z | - |
dc.date.issued | 2011-12 | - |
dc.identifier.issn | 1598-9100 | - |
dc.identifier.issn | 2288-1956 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/16093 | - |
dc.description.abstract | Background/Aims: The benefits and risks of concomitant immunomodulators with infliximab maintenance therapy in patients with luminal Crohn's disease (CD) have not been adequately evaluated. We studied the influence of immunomodulator discontinuation in patients in remission with infliximab therapy through a restrospective case-control study. Methods: Medical records of 37 patients with luminal CD who received infliximab at four medical centers were retrospectively analyzed. We compared clinical and follow-up data of patients who were treated with infliximab alone with that of patients with combination therapy. Results: Among 37 patients, 31 (83.7%) were treated with infliximab plus azathioprine and six (16.2%) were treated with infliximab alone. Of the 31 patients receiving combination maintenance therapy, 26 (83.9%) were in complete remission after 12 months, as compared with five of six patients (83.3%) receiving infliximab alone. No significant difference was observed in remission rate between two groups (P=0.735). In total, 16.1% of patients in combination therapy and 16.7% in infliximab alone group reported side effects (P=1.000), but serious adverse events such as reactivation of tuberculosis were noted in only one patient in combination therapy group. Conclusions: Concomitant immunomodulators did not improve efficacy in patients with luminal CD who received scheduled infliximab maintenance. | - |
dc.format.extent | 7 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.publisher | 대한장연구학회 | - |
dc.title | Comparison of Infliximab and Infliximab/Azathioprine for Maintenance Therapy in Korean Patients with Luminal Crohn's Disease | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.5217/ir.2011.9.3.189 | - |
dc.identifier.wosid | 000420054000003 | - |
dc.identifier.bibliographicCitation | Intestinal research, v.9, no.3, pp 189 - 195 | - |
dc.citation.title | Intestinal research | - |
dc.citation.volume | 9 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 189 | - |
dc.citation.endPage | 195 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001626849 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | INFLAMMATORY-BOWEL-DISEASE | - |
dc.subject.keywordPlus | ANTI-TNF | - |
dc.subject.keywordPlus | AZATHIOPRINE | - |
dc.subject.keywordAuthor | Crohn's Disease | - |
dc.subject.keywordAuthor | Infliximab | - |
dc.subject.keywordAuthor | Azathioprine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.